We're working to raise the bar in healthcare and impact millions of lives.​

By combining human ingenuity, the power of technology, and a belief in challenging the status quo, it’s our mission to create computationally intelligent products that revolutionize cardiology.​​

Executive team

About >

About >

About >

About >

About >

About >

About >

About >

About >

Inventors & Co-Founders

About >

About >

About >

Members Of The Board & Advisory Team
Mike Monko, Executive Chairman, Board of Directors

Mike is a recognized senior executive with over 20 years of leadership and management experience in the life science, biotech, and diagnostics industries. Mike has built and led successful teams responsible for upwards of $200M in global revenue. Mike co-founded Vektor in 2017 and led the company through development and launch of its first product before moving into his role as executive chairman. Prior to co-founding Vektor, Mike held executive positions at Life Technologies, Serologicals and, most recently, at Sequenom where he played an integral role in the successful sale of its Biosciences division to Telegraph Hill Partners, which became Agena Biosciences. Mike holds an MBA from Babson College and a B.S. from the University of New Hampshire.

Russell Dixon, Board Member

Russell is the president and CEO of the multi-billion-dollar investment enterprise, Redhill Investment Management, and its related companies. Russell has held key positions in national and global companies in both Private Equity and Real Estate Investment. Russell is an accomplished leader and businessman and has deep experience in investment and finance.

Lewis Waldman, Ph.D., Advisor and Affiliate

Dr. Lewis Waldman is CEO of Insilicomed, a biomedical consulting and clinical products company, and an affiliate of Vektor Medical. He is an internationally recognized leader in cardiovascular mechanics research and has taught and supervised students at UC San Diego, Carnegie-Mellon and Stanford. Dr. Waldman and Insilicomed have used multi-scale computational modeling to aid cardiac medical device design.

Robert Engler, M.D., Advisor

Dr. Robert Engler, UCSD Professor of Cardiovascular Medicine, published 93 peer reviewed publications in major journals and has extensive biotechnology experience. He founded two biotech companies based on his research, has served on 8 corporate boards, and advised on both science and business for drug, device, and gene therapy products.

Ulrika Birgersdotter-Green, M.D, Advisor

Dr. Birgersdotter-Green is a Professor of Medicine at UCSD and the Director of Pacemaker and ICD Services.  She has extensive experience in the design and conduct of clinical trials.  Dr. Birgersdotter-Green also serves on the Editorial Review Board for Heart Rhythm and the Journal of the American College of Cardiology.

Greg Feld, M.D., Advisor

Dr. Greg Feld is a Professor of Medicine at UCSD and an internationally recognized expert in cardiac electrophysiology. He serves as Director of the Cardiac Electrophysiology Program and Director of the Cardiac Electrophysiology Fellowship Training Program at UCSD.

Adam Geronemus, M.D. FSIR, Advisor

Dr. Adam Geronemus is the Vice Chairman of Education and Assistant Professor, Department of Interventional Radiology at the FIU College of Medicine. He is also an Assistant Clinical Professor for the Department of Radiology at the USF College of Medicine. In 2018 he was given the distinguished honor of being named a Fellow by the Society of Interventional Radiology.

Kalle Marsal, Advisor

Kalle is COO and Board Member of PetDx and has previously held a variety of senior leadership positions, including COO for a Nasdaq-listed mid-cap company and VP of Product Management at HP. He is an advisor to many successful organizations across several life-science and high-technology sectors.

San Diego:

9255 Towne Centre Drive, St 750,
San Diego, CA,


WeWork c/o Vektor Medical
3120 139th Avenue Southeast, St 500, Bellevue, WA,

Image of Mike Monko

Mike Monko

CEO, Co-Founder, and Member of the Board of Directors

Mike Monko is a recognized senior executive with over 20 years of leadership and management experience in the life science, biotech, and diagnostics industries. Prior to his leadership at Vektor, Mike served as an executive at Life Technologies, Serologicals, and Sequenom.

Robert Krummen, Esq.

President, Chief Operating Officer and Member of the Board of Directors

For nearly two decades, Rob Krummen has served in a variety of roles, leading and advising corporations, nonprofits, institutions of higher education, and state entities. Rob is a former partner at Vorys, Sater, Seymour and Pease LLP and a former Deputy Solicitor General for the State of Ohio. He had the privilege of clerking for the Honorable R. Guy Cole of the United States Court of Appeals for the Sixth Circuit. Rob earned his JD from Harvard Law School.

Dr. Christopher Villongco, Ph.D.

Chief Technology Officer, Inventor, and Co-Founder

Dr. Christopher Villongco has over a decade of experience in computational modeling and high-performance computing. He conducted doctoral and post-doctoral research in the Departments of Bioengineering and Medicine at the University of California, San Diego. His work focused on developing and applying patient-specific computational models of cardiac electrophysiology to solve real-world clinical problems, especially heart failure and arrhythmias.

Doug Komen

CFO and Member of the Board of Directors

Doug has over 25 years of executive-level finance, technology, risk management, and investment experience spanning more than 20 different industries. He was a founding partner in one of the first electronic derivative trading firms, a director and member of the Investment and Risk Committee, taught futures and options theory, has been a small business mentor, a CEO Coach, and has served on several boards in various roles, including managing a multi-asset class P.E. fund.

Kalle Marsal

Member of the Board of Directors

Kalle Marsal is a senior executive, board member, investor, and advisor to many successful ventures and non-profit organizations across several life-science and high-technology sectors. He served as COO for a Nasdaq-listed mid-cap company, is a former management consultant at Bain & Company, and is a former senior executive at HP. He earned his MBA and MS at Stanford University.

Emily Lovell

Director of Marketing & PR

Emily Lovell brings over a decade of marketing and PR experience to the Vektor team. Prior to joining Vektor, Emily worked for Etsy.com, leading strategic communications for the then relatively unknown start-up, through IPO and beyond. She is passionate about building and driving awareness for emerging businesses and has a wealth of experience developing and executing impactful, transparent, and informative campaigns.


Dr. David Krummen, MD, FACC, FHRS

Co-Founder, Inventor, and Clinical Advisor

Dr. David Krummen is a professor of medicine at the University of California San Diego and the director of electrophysiology at the VA San Diego Healthcare System. He is a recognized expert in cardiac arrhythmia research. He pioneered ventricular fibrillation electrical substrate ablation, and has authored more than 80 papers in the field.

Dr. Andrew McCulloch, Ph.D.

Co-Founder, Inventor, and Clinical Advisor

Dr. Andrew McCulloch is Distinguished Professor of Bioengineering and Medicine at UC San Diego and Director of the Institute of Engineering in Medicine. His laboratory has pioneered the use of multi-scale computational modeling both for elucidating the molecular mechanisms of heart disease and for patient-specific diagnosis and therapy planning in the clinical management of cardiac arrhythmias, heart failure, and congenital heart diseases.

Dr. Gordon Ho, MD, FACC, FHRS

Co-Founder, Inventor, and Clinical Advisor

Dr. Gordon Ho is an assistant professor of medicine at the University of California San Diego. He has more than 10 years of experience in computational modeling, ventricular fibrillation, and atrial fibrillation. Dr. Ho was recently awarded National Institutes of Health and American Heart Association career development grants to study the mechanisms of atrial fibrillation.